Romain Altwegg
Overview
Explore the profile of Romain Altwegg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
879
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cussac C, Riviere P, Altwegg R, Caillo L, Poullenot F, Laharie D, et al.
Aliment Pharmacol Ther
. 2025 Mar;
PMID: 40047405
This multicenter retrospective study examines 18 patients with difficult-to-treat inflammatory bowel diseases who received advanced combination treatment (ACT) with selective JAK1 inhibitors and biologics, totaling 11.8 patient-years of exposure. Treatment...
2.
Richard N, Amiot A, Seksik P, Altwegg R, Laharie D, Vuitton L, et al.
Aliment Pharmacol Ther
. 2025 Mar;
PMID: 40038887
Background: Real-world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear. Aims: This study aimed to evaluate the effectiveness and safety of upadacitinib in a real-world...
3.
Colin G, Girod M, Malezieux E, Altwegg R, Girard C
J Eur Acad Dermatol Venereol
. 2024 Dec;
PMID: 39644121
No abstract available.
4.
Amiot A, Seksik P, Meyer A, Stefanescu C, Wils P, Altwegg R, et al.
Gut
. 2024 Nov;
74(2):197-205.
PMID: 39586616
Background: It is unknown which maintenance therapy is the most effective option for patients admitted for an acute severe ulcerative colitis (ASUC) episode responding to intravenous steroids. Methods: We conducted...
5.
Le Cosquer G, Kirchgesner J, Gilletta De Saint Joseph C, Seksik P, Amiot A, Laharie D, et al.
Clin Gastroenterol Hepatol
. 2024 Nov;
PMID: 39505240
Background & Aims: Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD). The aim of our study was to evaluate incident cancer rate (recurrence...
6.
Reenaers C, Enea D, Nachury M, Laharie D, Bouhnik Y, Fumery M, et al.
J Crohns Colitis
. 2024 Nov;
PMID: 39487737
Background And Aims: Achieving deep remission, encompassing clinical, endoscopic, and biological remission, is the goal in managing Crohn's disease (CD). The role of histological remission remains unclear. This study aimed...
7.
Alonso-Gomez M, Charlois A, Cotte E, Gay C, Danion P, Malezieux E, et al.
Clin Res Hepatol Gastroenterol
. 2024 Sep;
48(9):102473.
PMID: 39349101
Background: Real life data about the long-term efficacy of darvadstrocel for treating perianal fistulas in Crohn's disease (CD) remain scarce. Aim: To report the effectiveness and safety of darvadstrocel therapy...
8.
Fumery M, Altwegg R, Aygalenq P, Filippi J, Ghestem V, Jamonneau I, et al.
Dig Liver Dis
. 2024 Sep;
57(1):251-259.
PMID: 39242250
Background: Specific studies on the impact of ulcerative colitis (UC) and bowel urgency (BU) on disability and quality of life (QoL) of patients on advanced therapies are missing. Methods: Clinical...
9.
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
Caron B, Seksik P, Buisson A, Wils P, Savoye G, Stefanescu C, et al.
Therap Adv Gastroenterol
. 2024 Aug;
17:17562848241265776.
PMID: 39119370
Background: Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown. Objectives: This study investigated IBD patient satisfaction with approved adalimumab...
10.
Sanavio M, Vauquelin B, Picot M, Altwegg R, Bozon A, Charpy F, et al.
Clin Res Hepatol Gastroenterol
. 2024 Jun;
48(7):102401.
PMID: 38897558
Introduction: The aim of this study was to compare the impact of the depth of myotomy (selective inner layer myotomy (SIM) vs. full-thickness myotomy (FTM)) on the outcome of patients...